Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A six-week, randomized, double-blind, quadruple-dummy parallel group multiple dose study comparing the efficacy and safety of tiotropium inhalation capsules plus formoterol inhalation capsules to salmeterol inhalation aerosol plus fluticasone inhalation aerosol in patients with chronic obstructive pulmonary disease (COPD)

Next Previous
X
Search
Trial Profile

A six-week, randomized, double-blind, quadruple-dummy parallel group multiple dose study comparing the efficacy and safety of tiotropium inhalation capsules plus formoterol inhalation capsules to salmeterol inhalation aerosol plus fluticasone inhalation aerosol in patients with chronic obstructive pulmonary disease (COPD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiotropium bromide (Primary) ; Fluticasone propionate; Formoterol; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Aug 2008 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
    • 01 Aug 2008 Results published in Chest journal.
    • 09 Jan 2008 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top